Updated phase 2 data showed a 60% ORR and 86% CNS ORR with frontline silevertinib in non-classical EGFR-mutant NSCLC; FDA discussion supported a phase 3 trial in 2027.
|Videos|April 18, 2017
Advanced Squamous Non-Small Cell Lung Cancer: Case 2
Advanced Squamous Non-Small Cell Lung Cancer
Advertisement
March 2017
- A 70-year-old female presents with shortness of breath and right-sided chest pain of 3 months’ duration
- She has a 25-year (1-pack/day) smoking history
- Chest X-ray revealed a pathologic fracture of the right 4th rib and a large right-sided pleural effusion
- CT scan confirmed the presence of a 3 cm spiculated mass in the right upper lobe, moderate right pleural effusion, and multiple lytic lesions in the spine and ribs
- Core needle biopsy of the lung mass was performed
- Pathology showed poorly differentiated lung squamous cell carcinoma, p63+ and CK5/6+ with abundant cytokeratin
- Genetic testing was negative for known driver mutations
- PD-L1 testing by IHC showed expression in 20% of cells
- The patient received palliative radiation therapy to the rib
- Options for systemic therapy are under discussion
Advertisement
Related to this article
FDA issues a not approvable letter for Novocure’s Optune Mya in NSCLC brain metastases, citing uncertain clinical benefit. No safety concerns were raised.
Imneskibart showed promising outcomes and tolerability in patients who had previously received immune checkpoint inhibition for either melanoma or lung adenocarcinoma.
In KEYNOTE-867, adding pembrolizumab to radiotherapy did not extend event-free survival in inoperable early-stage NSCLC and raised toxicity; the phase 3 trial was stopped for futility in 2024.
Advertisement
Advertisement
Trending on Targeted Onc
1
FDA Approves OncoMate MSI Dx For Pembrolizumab in MSI-H Tumors
2
Novocure’s Optune Mya Gets FDA Not Approvable Letter
3
Anbal-Cel Demonstrates Clinical Activity in Relapsed LBCL
4
In Phase 3, Ponatinib/Blinatumomab Improves EFS in Ph+ ALL
5